News | June 28, 2022

Assessing Drug-Induced Gut Toxicity In Vitro Webinar Announced For July 27

Altis Biosystems

The gastrointestinal (GI) tract is one of the most common organs affected by adverse drug reactions. While it is essential to assess GI toxicity early in drug development, traditional toxicity assays using model cell lines do not accurately reflect the human gut. Stem cell-based technologies that recreate the human intestine enable researchers to better evaluate drug-induced GI toxicity during candidate drug screening. In this webinar, experts from Altis Biosystems will discuss the latest advances of GI toxicity assessment empowered by stem cell and organ-on-a-chip technology.

Topics to be covered

  • Challenges of assessing GI risk in drug development
  • Assessing GI toxicity using an in vitro intestinal stem cell model 

Register for the Webinar

Current approaches to drug development have resulted in an 88% failure rate in clinical trials and $151 billion spent every year on research and development. A key factor driving this failure rate is the use of Caco-2 cells (cancer cells) and animal testing, which are an essential part of preclinical trials and yet cannot accurately predict human results.

That’s why Altis developed a next-generation intestinal platform that produces a layer of human intestinal stem and differentiated cells – either of the large or small intestine – that can be used for compound screening, disease modeling, and microbiome research. It can also be used to study many aspects of drug disposition including toxicity, metabolism, drug absorption, and efficacy.

Altis Biosystems is a spin-out company from the University of North Carolina at Chapel Hill and based in Durham, North Carolina. The intellectual property behind its stem cell platform was created as part of an NIH Transformative Research Award to develop a microfluidic organ-on-a-chip mimic of the human colon and awarded to Altis’ scientific founders. We are proud to have industry leading scientists on our team, capable of disrupting preclinical studies, and accelerating drug development to produce more effective drugs.

Source: Altis Biosystems